NICE

UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy

In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior recommendation was not to approve Zytiga. TAccording to NICE their decision to change their December 2015 recommendation follows the submission [...]

By Malecare|2017-10-19T10:46:36-04:00March 28th, 2016|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, NICE, Politics of Cancer, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|0 Comments

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]

By Malecare|2015-12-22T16:55:53-05:00December 22nd, 2015|abiraterone acetate,